Wellbiotec Co., Ltd.

As of June 30, 2025, Wellbiotec Co., Ltd. has 90.92M shares outstanding.

These figures are as of June 30, 2025. The price-to-sales ratio is 0.60, and the price-to-book ratio stands at -0.35.

As of June 30, 2025, Wellbiotec Co., Ltd. trades at an EV/EBITDA multiple of 0.00 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 0.54 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 0.00 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. Wellbiotec Co., Ltd. trades at an EV/FCF ratio of 47.22, comparing the total takeover cost of the business to the cash it actually generates for all capital providers.

As of June 30, 2025, Wellbiotec Co., Ltd. maintains a current ratio of 2.10, meaning it holds 2.1x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended June 30, 2025. Return on assets (ROA) is negative at -50.61, reflecting losses generated across the asset base. Inventory turnover of 2,454.87 indicates how many times Wellbiotec Co., Ltd. sells and replaces its inventory over a year, a key working capital efficiency ratio.

As of the close on January 23, 2026, Wellbiotec Co., Ltd.'s stock has declined approximately 97.98% over the past 52 weeks. The 50-day moving average sits at 506.22, while the 200-day moving average is 1,444.16.

Over the twelve months ended June 30, 2025, Wellbiotec Co., Ltd. posted a gross margin of 12.38, reflecting its pricing power and cost economics. The operating margin of -0.94 and net profit margin of -22.64 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2025. Free cash flow yield stands at 1.90, showing how much cash the business generates relative to its market value - dividends covered by free cash flow are generally more durable than those funded by debt. Total shareholder yield reaches 3.29, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to Wellbiotec Co., Ltd. shareholders.

Wellbiotec Co., Ltd.'s most recent stock split took place on October 28, 2011 with a 10:1 split ratio.

As of June 30, 2025, Wellbiotec Co., Ltd. has an Altman Z-Score of -3.40, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.